P&G plots sale of pharma brands

Procter & Gamble wants to bail out of the pharmaceuticals business, so it has hired Goldman Sachs to find buyers for its drug brands--or figure out another way to make a graceful exit, the Financial Times reports. Known primarily for its consumer goods, P&G also has a pharma unit that brings in about $2 billion a year. Its drugs are clustered around women's health, gastrointestinal problems and musculoskeletal disorders.

The move isn't a huge surprise; P&G told analysts back in December that the company had stopped investing in drug development and would consider selling off some of its pharma brands. Back in the 1990s, when P&G started putting big bucks into pharma, returns had dwarfed those in consumer products, CEO A.G. Lafley (photo) said. That's not the case now: "Today, pharma companies trade at multiples at or below consumer products."

Plus, pharma has to contend with a harsher regulatory environment nowadays, and generics makers have grown increasingly aggressive about competing with branded meds, so the payoff from R&D isn't as certain as it once was, he said.

- read the FT story

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.